Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Cancer Localization in the Prostate With F-18 Fluorocholine Positron Emission Tomography

This study has been completed.
United States Department of Defense
Information provided by (Responsible Party):
Queen's Medical Centre Identifier:
First received: June 24, 2009
Last updated: October 1, 2015
Last verified: October 2015
The purpose of this project is to develop and evaluate fluorine-18 (F-18) fluorocholine (FCH) positron emission tomography (PET) as an imaging technique that can be used to delineate malignant tumors in the prostate gland. The proposed technique works by measuring the tissue metabolism of FCH, a substrate that is preferentially metabolized by cancer cells due to malignant over-expression of the choline transporter and choline kinase enzyme. The project scope covers a clinical study to recruit men with prostate cancer who have elected treatment by radical prostatectomy surgery. These men will undergo pre-operative PET scanning to measure F-18 FCH uptake in anatomical sextants of the prostate gland. Imaging results will be compared to histopathologic analyses of the prostatectomy specimen to determine the accuracy of F-18 FCH PET for detecting cancerous prostate sextants.

Condition Intervention Phase
Prostate Cancer
Device: Fluourine-18 Fluoromethylcholine PET/CT Imaging
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Cancer Localization in the Prostate With F-18 Fluorocholine Positron Emission Tomography

Resource links provided by NLM:

Further study details as provided by Queen's Medical Centre:

Primary Outcome Measures:
  • Histopathologic Diagnosis - sextant diagnosis by whole-prostate step section histopathologic analysis [ Time Frame: Immediate - no longitudinal data collected ]

Enrollment: 20
Study Start Date: June 2004
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Investigational Imaging Device
Device: Fluourine-18 Fluoromethylcholine PET/CT Imaging
Single-dose Study
Other Names:
  • 18F-choline PET/CT
  • Fluorocholine PET/CT


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinically Organ Confined Prostate Cancer Electing Radical Prostatectomy

Exclusion Criteria:

  • Weight > 300 lb
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01310192

United States, Hawaii
Tripler Army Medical Center
Tripler, Hawaii, United States
Sponsors and Collaborators
Queen's Medical Centre
United States Department of Defense